Mr. Peter Puccetti reports

COSCIENS BIOPHARMA INC. ANNOUNCES RESULTS OF SHAREHOLDER MEETING AND APPOINTMENT OF FULL-TIME CEO

Cosciens Biopharma Inc. has released the results from its annual general and special meeting of shareholders.

At the meeting, all matters put to shareholders for consideration and approval, as set out in the company's management proxy circular dated May 18, 2026, were approved by the requisite number of votes cast at the meeting, including: (1) the re-election of all director nominees; (2) the reappointment of Deloitte LLP as the auditor; and (3) the authorization to proceed with the changes in the company's share capital, consisting of (i) the consolidation of the company's common shares on the basis of one postconsolidation common share for every 150 preconsolidation common shares; and (ii) the immediate subsequent split of the common shares on the basis of 50 common shares for every postconsolidation common share.

The complete voting results of all matters voted on at the meeting are available on SEDAR+ under the company's issuer profile on SEDAR+.

The company will provide further information with respect to the proposed share capital amendment in due course.

Peter H. Puccetti appointed as full-time chief executive officer

The company is also pleased to announce that Mr. Puccetti, chairman of the company's board of directors, and who has been serving as interim chief executive officer since November, has been appointed as the company's permanent full-time president and CEO, effective immediately. In his role, Mr. Puccetti will continue to aim to strengthen operational performance and align resources with key strategic priorities, building upon the objectives advanced during his interim tenure.

Mr. Puccetti said, "Along with the rest of the board, I am looking forward to building upon the improved foundation we now have at Cosciens. Shareholder value creation is our prime focus and we are encouraged by our early efforts in this regard."

About Cosciens Biopharma Inc.

Cosciens is a holding company, operating through its subsidiaries. Cosciens's principal operating subsidiary, Ceapro Inc., is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro's primary active ingredient business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using proprietary technology, natural, renewable resources and developing innovative products, technologies and delivery systems.

The company's common shares are listed on the Toronto Stock Exchange under the symbol CSCI and are listed and posted for trading on the OTCQB Venture Market under the symbol CSCIF.

We seek Safe Harbor.